Intraoperative diuretics during deceased-donor kidney transplants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, prospective, randomized pilot study compares two intraoperative diuretics—furosemide and mannitol—in adult recipients of deceased-donor kidney transplants. Participants are randomized 1:1, stratified by donor type, and surgeon-blinded to the diuretic used. The goal is to determine if one agent more effectively reduces the risk of delayed graft function, defined as dialysis within the first seven days post-transplant. DGF is a common complication linked to longer hospital stays and higher rejection risk, potentially impacting long-term graft survival. The trial will enroll up to 240 participants at London Health Sciences Centre to inform future practice and larger studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \>18 years;
2. Patient is scheduled to receive a deceased-donor kidney transplant (including both NDD and DCD donors)
3. Patient is willing and able to provide written and informed consent, or a substitute decision maker (SDM) is available to sign on the patient's behalf

Exclusion Criteria:

1. Patient is receiving another organ at the time of their kidney transplant (e.g., simultaneous kidney-pancreas or kidney-liver)
2. Known allergy or contraindication to mannitol or furosemide
3. Inability to provide informed consent
4. Pediatric recipients (\<18 years of age)
5. Previously enrolled in this clinical trial

Where it's running

• University Hospital - London Health Sciences Centre
  London, Ontario, Canada Recruiting
• London Health Sciences Centre
  London, Ontario, Canada Not yet recruiting

Study contacts

• Study coordinator: Cadence Research Manager, BSc, MSc
• Email: Cadence.Baker@lhsc.on.ca
• Phone: (519) 685-8500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vonoprazan to reduce delayed graft function after deceased-donor kidney transplant

  This trial will test whether giving vonoprazan around the time of surgery lowers the chance of delayed graft function in adults receiving their first deceased-donor kidney transplant.

  Recruiting Phase 1/2 First Affiliated Hospital of Chongqing Medical University · Chongqing and 1 other locations · NCT07275632

• Italian Registry of Pediatric Dialysis: collecting data from kids on kidney replacement therapy

  This registry in Italy tests how collecting epidemiological, clinical, and treatment data from children on dialysis or pre-emptive kidney transplants can help centers share protocols and improve care.

  Recruiting at 12 sites Istituto Giannina Gaslini · Ancona and 11 other locations · NCT07918066

• Immune Reset to Enable Kidney Transplant for Highly Sensitized Patients

  This study tests whether a temporary immune system reboot using a patient’s own stem cells can help highly sensitized kidney patients receive a compatible transplant.

  Recruiting Phase 1/2 Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Catalonia · NCT07607197

• Home-based exercise to boost fitness for people waiting for a kidney transplant

  This study tests whether a 12-week, home-based exercise program plus a wearable activity tracker helps adults on the kidney transplant waiting list increase daily activity and improve physical function.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07446296

• A six-week online self-management program for adults in Israel with chronic conditions

  This six-week online group program will try to help adults in Israel who have chronic conditions—such as cancer survivors or kidney transplant recipients—learn practical skills to manage symptoms and daily health.

  Recruiting University of Haifa · Tel Aviv · NCT07367750

• GGTA1 KO pig kidney with thymus for people with end-stage kidney failure

  This test tries a genetically modified pig kidney with attached thymus tissue (GGTA1 KO Thymokidney) in people with end-stage kidney failure who either can't get a human donor kidney or are unlikely to get one within five years.

  Recruiting Phase 1/2 United Therapeutics · New York, New York · NCT07224763

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.